CEL-SCI Summarizes Significant Accomplishments In 2015 And Positive Momentum For 2016
VIENNA, Va.--(BUSINESS WIRE)--The following letter is being released by CEL-SCI Corporation (NYSE MKT: CVM) to its shareholders:
Dear Fellow Shareholders:
As CEL-SCI shareholders most of you have been following the progress in our Phase 3 head and neck cancer trial, the largest of its kind in the world. We are proud of what we have achieved in 2015. Before summarizing our accomplishments during the year, I want to first thank each of you for choosing to support us in an enormous and ambitious undertaking. We believe that we can bring the promise of immunotherapy to treating newly diagnosed cancer patients when they can benefit from it most, before their immune systems are compromised by the existing cancer standard of care treatments.
Dear Fellow Shareholders:
As CEL-SCI shareholders most of you have been following the progress in our Phase 3 head and neck cancer trial, the largest of its kind in the world. We are proud of what we have achieved in 2015. Before summarizing our accomplishments during the year, I want to first thank each of you for choosing to support us in an enormous and ambitious undertaking. We believe that we can bring the promise of immunotherapy to treating newly diagnosed cancer patients when they can benefit from it most, before their immune systems are compromised by the existing cancer standard of care treatments.